Q1 Earnings Forecast for PRAX Issued By HC Wainwright

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Praxis Precision Medicines in a report released on Monday, July 14th. HC Wainwright analyst D. Tsao expects that the company will post earnings of ($4.32) per share for the quarter. HC Wainwright has a “Buy” rating and a $105.00 price objective on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. HC Wainwright also issued estimates for Praxis Precision Medicines’ Q2 2026 earnings at ($5.01) EPS, Q3 2026 earnings at ($5.02) EPS and Q4 2026 earnings at ($5.03) EPS.

PRAX has been the subject of several other reports. Wedbush upped their target price on Praxis Precision Medicines from $26.00 to $28.00 and gave the company an “underperform” rating in a research note on Monday, May 5th. Needham & Company LLC reiterated a “buy” rating and issued a $80.00 target price on shares of Praxis Precision Medicines in a research note on Thursday, June 12th. Oppenheimer upped their target price on Praxis Precision Medicines from $97.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. Finally, Chardan Capital initiated coverage on Praxis Precision Medicines in a research note on Wednesday, May 7th. They set a “buy” rating and a $80.00 price target for the company. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $94.11.

Praxis Precision Medicines Trading Up 3.4%

Praxis Precision Medicines stock opened at $53.63 on Wednesday. The firm has a market capitalization of $1.09 billion, a P/E ratio of -5.00 and a beta of 2.60. The stock has a fifty day moving average price of $42.73 and a 200 day moving average price of $50.59. Praxis Precision Medicines has a 52 week low of $26.70 and a 52 week high of $91.83.

Praxis Precision Medicines (NASDAQ:PRAX) last released its quarterly earnings results on Friday, May 2nd. The company reported ($3.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.20) by ($0.09). Praxis Precision Medicines had a negative return on equity of 50.42% and a negative net margin of 2,137.48%.

Institutional Trading of Praxis Precision Medicines

Several institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System raised its position in shares of Praxis Precision Medicines by 2.2% during the 4th quarter. California State Teachers Retirement System now owns 12,726 shares of the company’s stock worth $979,000 after purchasing an additional 275 shares during the period. GAMMA Investing LLC boosted its stake in shares of Praxis Precision Medicines by 6,075.4% during the 1st quarter. GAMMA Investing LLC now owns 4,014 shares of the company’s stock worth $152,000 after acquiring an additional 3,949 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Praxis Precision Medicines by 6.7% during the 1st quarter. Rhumbline Advisers now owns 24,294 shares of the company’s stock worth $920,000 after acquiring an additional 1,525 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Praxis Precision Medicines in the fourth quarter worth $248,000. Finally, Vanguard Group Inc. boosted its position in shares of Praxis Precision Medicines by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 1,063,639 shares of the company’s stock worth $81,858,000 after buying an additional 24,645 shares during the period. Institutional investors and hedge funds own 67.84% of the company’s stock.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.